Pulmatrix (PULM) Capital Expenditures (2014 - 2025)
Pulmatrix (PULM) posted Capital Expenditures of -$13000.0 for Q1 2025, down 102.5% sequentially from $520000.0 in Q4 2024, and up 68.29% YoY from -$7724.6 in Q1 2024.
Pulmatrix (PULM) Capital Expenditures (2014 - 2025) Analysis & Trends
Pulmatrix has reported Capital Expenditures for 12 years, with the latest figure at -$13000.0 in Q1 2025.
- Quarterly Capital Expenditures rose 68.29% year-over-year to -$13000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$13000.0 (down 103.27% YoY) and the FY2025 annual result came in at -$13000.0, down 103.27% from the prior year.
- Capital Expenditures retreated to -$13000.0 in Q1 2025 per PULM's latest filing, from $520000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $606000.0 in Q3 2023 and troughed at -$877000.0 in Q4 2023.
- A 5-year average of $45800.0 and a median of $26000.0 in 2021 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 5000.0% in 2023, down 2148.72% in 2023.
- Over 5 years, Capital Expenditures stood at $26000.0 in 2021, then tumbled by 250.0% to -$39000.0 in 2022, then slumped by 2148.72% to -$877000.0 in 2023, then soared by 159.29% to $520000.0 in 2024, then tumbled by 102.5% to -$13000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$13000.0, $520000.0, and -$520000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Pulmatrix | 5.62 Mn | 5.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -13,000.00 |
| Mar 31, 2025 | -13,000.00 |
| Dec 31, 2024 | 520,000.00 |
| Dec 31, 2024 | 520,000.00 |
| Sep 30, 2024 | -520,000.00 |
| Sep 30, 2024 | -520,000.00 |
| Jun 30, 2024 | 439,000.00 |
| Jun 30, 2024 | 439,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Dec 31, 2023 | -877,000.00 |
| Dec 31, 2023 | -877,000.00 |
| Sep 30, 2023 | 606,000.00 |
| Sep 30, 2023 | 606,000.00 |
| Jun 30, 2023 | -452,000.00 |
| Jun 30, 2023 | -452,000.00 |
| Mar 31, 2023 | 510,000.00 |
| Mar 31, 2023 | 510,000.00 |
| Dec 31, 2022 | -39,000.00 |
| Dec 31, 2022 | -39,000.00 |